PharmaBoardroom today releases its new 58-page Healthcare & Life Sciences Review Singapore 2017.
This report offers companies, investors, policymakers, and stakeholders crucial insight into Singapore; a nation that has had to carve out its own niche as a global trade hub and gateway to the Asia-Pacific region to compete globally since declaring independence in 1965. In terms of healthcare and life sciences, the island now serves as a regional hub for myriad multinationals, stands at the forefront of cutting-edge scientific research and development, and is globally renowned in several important levels of the pharmaceutical supply chain.
The report features in-depth exclusive interviews with leading figures from public institutions and private companies, comprehensive articles, and up-to-date facts and figures on Singapore’s healthcare and pharma sectors.
Featured topics include:
- Singapore’s Economic Strategy and Development History
- A New Model of Asian Healthcare
- R&D and Cutting-Edge Biotech
- Singapore’s Leading Global Position in Healthcare Logistics
- The Transformative Potential of Digitalization
The report features in-depth interviews with:
- Weng Si Ho, EDB
- Fredrik Nyberg APACMed
- Giles Platford, Takeda
- Bob White, Medtronic
- Sugantha Natarajan, DB Schenker
- Christoper Snook, Novartis
- Peter Meinshausen and Dr. Stefan Randl, Evonik
- Ong Wee Min, Marina Bay Sands
- Elisabeth Staudinger, Siemens Healthineers
“Singapore is the example of how efficiency can be improved when the government and the industry work together collaboratively”
Ti Hwei How, SAPI
“With roughly hald of the world’s population here in Asia Pacific, we see an increase in unmet medical needs which will continue to grow with aging populations and the surge of chronic diseases”
Gary Pruden, J&J
“Singapore is an excellent engineering and microelectronics hub so the technology is of the best calibre here”
Michael Tillmann, Vela Diagnostics
“APAC is estimated at 25 percent of the global economy and within 10 years it is expected to grow to 35 percent.”
Martin Dewhurst, McKinsey & Company
Click here to register and download the report.